

Newly Reported Substances: The following substances were reported to NFLIS-Drug for the first time between April 1, 2023, and June 30, 2023.



West



Midwest




South




Northeast


N-Ethyl norfentanyl




ADB-5Br-4en-PINACA




N-Pyrrolidino metonitazene




Methylmethaqualone




Paynantheine




ADB-INACA



4F- α -PiHP




N-Pyrrolidino protonitazene



South and Northeast

N-Piperidinylnitazene




Snapshot of Drug Reports Received by NFLIS-Drug

The tables on the right present the top five drug reports in each category received by NFLIS-Drug between April 1, 2023, and June 30, 2023.


Benzodiazepines	7,347	Synthetic Cannabinoids	1,241	Depressants and Tranquilizers	5,301
Alprazolam	3,310	MDMB-en-PINACA ¹	629	Xylazine	3,417
Clonazepam	1,168	ADB-BUTINACA	241	Ketamine	638
Bromazolam	1,165	AB-CHMINACA	39	Phencyclidine (PCP)	617
Clonazolam	514	ADB-en-PINACA ¹	23	Cyclobenzaprine	114
Diazepam	363	MDMB-BINACA	21	Carisoprodol	106

¹ Includes all positional and nonspecified isomers as reported by participating laboratories.


Upward Trends, by Date Submitted to Laboratory



Protonitazene



Acetyl fentanyl



Ketamine

Note: A reliable percentage for June 2023 could not be calculated because of the small proportion of expected total reports received by NFLIS-Drug at the time of analysis.

Data Disclaimer: Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in July 2023. Data in the Newly Reported Substances and Snapshot of Drug Reports Received by NFLIS-Drug sections include only drugs submitted to laboratories on or after April 1, 2022. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.deadiversion.usdoj.gov/nflisdata/docs/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.deadiversion.usdoj.gov/publicationsRedesign.xhtml>. Questions and comments: NFLIS@dea.gov

